AR and prostate cancer: Such as targeting the SWI/SNF complex, which regulates abnormal chromatin remodeling, disrupting the transcriptional expression of super‐enhancer‐driven genes like AR, FOXA1, ERG and MYC, as well as their regulatory programs on downstream genes in prostate cancer.[39] LSD1, BRD4 and FOXA1 form a transcriptional regulatory loop, binding to super‐enhancer elements to regulate the transcription of target genes.